Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status.
Chromosome 11q
Chromosome 1p
Immune status
MYCN
Neuroblastoma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
received:
09
11
2023
accepted:
08
10
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
15
10
2024
Statut:
epublish
Résumé
Neuroblastoma exhibits substantial heterogeneity, which is intricately linked to various genetic alterations. We aimed to explore immune status in the peripheral blood and prognosis of patients with neuroblastoma with different genetic characteristics. We enrolled 31 patients with neuroblastoma and collected samples to detect three genetic characteristics. Peripheral blood samples were tested for immune cells and cytokines by fluorescent microspheres conjugated with antibodies and flow cytometry. Event-free survival (EFS) was analyzed using the Kaplan‒Meier method. Twenty-two patients had genetic aberrations, including MYCN amplification in 6 patients, chromosome 1p deletion in 9 patients, and chromosome 11q deletion in 14 patients. Two genetic alterations were present in seven patients. The EFS was worse in patients with MYCN amplification or 1p deletion than in the corresponding group, whereas 11q deletion was a prognostic factor only in patients with unamplified MYCN. Changes in immune status revealed a decrease in the proportion of T cells in blood, and an increase in regulatory T cells and immunosuppression-related cytokines such as interleukin (IL)-10. The EFS of the IL-10 high-level group was lower than that of the low-level group. Patients with concomitant genetic alterations and a high level of IL-10 had worse EFS than other patients. Patients with neuroblastoma characterized by these genetic characteristics often have suppressed T cell response and an overabundance of immunosuppressive cells and cytokines in the peripheral blood. This imbalance is significantly associated with poor EFS. Moreover, if these patients show an elevated levels of immunosuppressive cytokines such as IL-10, the prognosis will be worse.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroblastoma exhibits substantial heterogeneity, which is intricately linked to various genetic alterations. We aimed to explore immune status in the peripheral blood and prognosis of patients with neuroblastoma with different genetic characteristics.
METHODS
METHODS
We enrolled 31 patients with neuroblastoma and collected samples to detect three genetic characteristics. Peripheral blood samples were tested for immune cells and cytokines by fluorescent microspheres conjugated with antibodies and flow cytometry. Event-free survival (EFS) was analyzed using the Kaplan‒Meier method.
RESULTS
RESULTS
Twenty-two patients had genetic aberrations, including MYCN amplification in 6 patients, chromosome 1p deletion in 9 patients, and chromosome 11q deletion in 14 patients. Two genetic alterations were present in seven patients. The EFS was worse in patients with MYCN amplification or 1p deletion than in the corresponding group, whereas 11q deletion was a prognostic factor only in patients with unamplified MYCN. Changes in immune status revealed a decrease in the proportion of T cells in blood, and an increase in regulatory T cells and immunosuppression-related cytokines such as interleukin (IL)-10. The EFS of the IL-10 high-level group was lower than that of the low-level group. Patients with concomitant genetic alterations and a high level of IL-10 had worse EFS than other patients.
CONCLUSIONS
CONCLUSIONS
Patients with neuroblastoma characterized by these genetic characteristics often have suppressed T cell response and an overabundance of immunosuppressive cells and cytokines in the peripheral blood. This imbalance is significantly associated with poor EFS. Moreover, if these patients show an elevated levels of immunosuppressive cytokines such as IL-10, the prognosis will be worse.
Identifiants
pubmed: 39407175
doi: 10.1186/s12885-024-13044-5
pii: 10.1186/s12885-024-13044-5
doi:
Substances chimiques
N-Myc Proto-Oncogene Protein
0
MYCN protein, human
0
Interleukin-10
130068-27-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1279Subventions
Organisme : Tianjin health research project
ID : TJWJ2021MS010
Organisme : National Key Research and Development Program of China
ID : 2018YFC1313000
Informations de copyright
© 2024. The Author(s).
Références
Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2015;62(1):225–56.
pubmed: 25435121
doi: 10.1016/j.pcl.2014.09.015
Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma Lancet. 2007;369(9579):2106–20.
pubmed: 17586306
doi: 10.1016/S0140-6736(07)60983-0
Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022;19(8):515–33.
pubmed: 35614230
doi: 10.1038/s41571-022-00643-z
London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children’s Oncology Group. J Clin Oncol. 2005;23(27):6459–65.
pubmed: 16116153
doi: 10.1200/JCO.2005.05.571
D’Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet. 1971;1(7708):1046–9.
pubmed: 4102970
doi: 10.1016/S0140-6736(71)91606-0
Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26(9):1504–10.
pubmed: 18349403
doi: 10.1200/JCO.2007.12.3349
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017;18(7):946–57.
pubmed: 28549783
pmcid: 5527694
doi: 10.1016/S1470-2045(17)30355-8
Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer. 2017;64(1):25–31.
pubmed: 27555472
doi: 10.1002/pbc.26192
Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma Nat Rev Dis Primers. 2016;2:16078.
pubmed: 27830764
doi: 10.1038/nrdp.2016.78
Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45(3):279–84.
pubmed: 23334666
pmcid: 3682833
doi: 10.1038/ng.2529
Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27(7):1026–33.
pubmed: 19171713
doi: 10.1200/JCO.2008.16.0630
Shi H, Tao T, Abraham BJ, Durbin AD, Zimmerman MW, Kadoch C, et al. ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Sci Adv. 2020;6(29):eaaz3440.
pubmed: 32832616
pmcid: 7439613
doi: 10.1126/sciadv.aaz3440
Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013;45(1):12–7.
pubmed: 23202128
doi: 10.1038/ng.2493
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–4.
pubmed: 6719137
doi: 10.1126/science.6719137
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313(18):1111–6.
pubmed: 4047115
doi: 10.1056/NEJM198510313131802
Onal S, Turker-Burhan M, Bati-Ayaz G, Yanik H, Pesen-Okvur D. Breast cancer cells and macrophages in a paracrine-juxtacrine loop. Biomaterials. 2021;267:120412.
pubmed: 33161320
doi: 10.1016/j.biomaterials.2020.120412
Meurette O, Mehlen P. Notch Signaling in the Tumor Microenvironment. Cancer Cell. 2018;34(4):536–48.
pubmed: 30146333
doi: 10.1016/j.ccell.2018.07.009
van Weverwijk A, de Visser KE. Mechanisms driving the immunoregulatory function of cancer cells. Nat Rev Cancer. 2023;23(4):193–215.
Garner H, de Visser KE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol. 2020;20(8):483–97.
pubmed: 32024984
doi: 10.1038/s41577-019-0271-z
Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312.
pubmed: 33750922
doi: 10.1038/s41568-021-00339-z
He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–9.
pubmed: 32467592
pmcid: 7395714
doi: 10.1038/s41422-020-0343-4
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30.
pubmed: 28102259
doi: 10.1038/nature21349
Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–84.
pubmed: 30275043
pmcid: 6169832
doi: 10.1101/gad.314617.118
Palucka AK, Coussens LM. The basis of Oncoimmunology. Cell. 2016;164(6):1233–47.
pubmed: 26967289
pmcid: 4788788
doi: 10.1016/j.cell.2016.01.049
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812–30. e14.
pubmed: 29628290
pmcid: 5982584
doi: 10.1016/j.immuni.2018.03.023
Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11.
pubmed: 20558371
pmcid: 3306838
doi: 10.1056/NEJMra0804577
Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2011;105(12):1940–8.
pubmed: 22146831
pmcid: 3251887
doi: 10.1038/bjc.2011.472
Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, Nilsson S, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010;107(9):4323–8.
pubmed: 20145112
pmcid: 2840092
doi: 10.1073/pnas.0910684107
Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol. 2010;28(19):3122–30.
pubmed: 20516441
doi: 10.1200/JCO.2009.26.7955
Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, et al. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. Br J Cancer. 2015;112(2):290–5.
pubmed: 25356804
doi: 10.1038/bjc.2014.557
Ambros IM, Tonini GP, Potschger U, Gross N, Mosseri V, Beiske K, et al. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report from the SIOPEN Biology Group on the LNESG trials and a COG Validation Group. J Clin Oncol. 2020;38(31):3685–97.
pubmed: 32903140
pmcid: 7605396
doi: 10.1200/JCO.18.02132
Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, et al. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61(11):1932–9.
pubmed: 25044743
doi: 10.1002/pbc.25134
Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353(21):2243–53.
pubmed: 16306521
doi: 10.1056/NEJMoa052399
Selmi A, de Saint-Jean M, Jallas AC, Garin E, Hogarty MD, Benard J, et al. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Cancer Lett. 2015;357(1):412–8.
pubmed: 25475555
doi: 10.1016/j.canlet.2014.11.056
Floros KV, Cai J, Jacob S, Kurupi R, Fairchild CK, Shende M, et al. MYCN-Amplified neuroblastoma is addicted to Iron and vulnerable to inhibition of the System Xc-/Glutathione Axis. Cancer Res. 2021;81(7):1896–908.
pubmed: 33483374
pmcid: 9281612
doi: 10.1158/0008-5472.CAN-20-1641
Maris JM, Guo C, White PS, Hogarty MD, Thompson PM, Stram DO, et al. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol. 2001;36(1):24–7.
pubmed: 11464895
doi: 10.1002/1096-911X(20010101)36:1<24::AID-MPO1007>3.0.CO;2-7
Yagyu S, Iehara T, Gotoh T, Miyachi M, Katsumi Y, Kikuchi K, et al. Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: a novel diagnostic tool for therapy stratification of neuroblastoma. Cancer Lett. 2011;309(2):185–9.
pubmed: 21726937
doi: 10.1016/j.canlet.2011.05.032
Yue ZX, Xing TY, Gao C, Liu SG, Zhao W, Zhao Q, et al. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification. Cancer Commun (Lond). 2019;39(1):68.
pubmed: 31685009
Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer. 2001;91(5):680–6.
pubmed: 11267980
doi: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R
Siaw JT, Javanmardi N, Van den Eynden J, Lind DE, Fransson S, Martinez-Monleon A, et al. 11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in Neuroblastoma. Cell Rep. 2020;32(12):108171.
pubmed: 32966799
doi: 10.1016/j.celrep.2020.108171
Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006;12(11 Pt 1):3368–73.
pubmed: 16740759
doi: 10.1158/1078-0432.CCR-05-2495
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Mina M, Boldrini R, Citti A, Romania P, D’Alicandro V, De Ioris M, et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology. 2015;4(9):e1019981.
pubmed: 26405592
pmcid: 4570119
doi: 10.1080/2162402X.2015.1019981
Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.
pubmed: 23639322
doi: 10.1016/S1470-2045(12)70582-X
Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205–18.
pubmed: 19161426
pmcid: 2724982
doi: 10.1111/j.1600-065X.2008.00706.x
Sallusto F. Heterogeneity of human CD4(+) T cells against microbes. Annu Rev Immunol. 2016;34:317–34.
pubmed: 27168241
doi: 10.1146/annurev-immunol-032414-112056
DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010;29(2):309–16.
pubmed: 20405169
pmcid: 2865635
doi: 10.1007/s10555-010-9223-6
Ugel S, Cane S, De Sanctis F, Bronte V. Monocytes in the Tumor Microenvironment. Annu Rev Pathol. 2021;16:93–122.
pubmed: 33497262
doi: 10.1146/annurev-pathmechdis-012418-013058
Sherif S, Roelands J, Mifsud W, Ahmed EI, Raynaud CM, Rinchai D, et al. The immune landscape of solid pediatric tumors. J Exp Clin Cancer Res. 2022;41(1):199.
pubmed: 35690832
pmcid: 9188257
doi: 10.1186/s13046-022-02397-z